CM-4307

Generic Name: CM-4307

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₆ClF_₃N_₄O_₃

CAS Number: 1130115-44-4

Unique Ingredient Identifier: 41XGO0VS1U

Background: CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).

Indication: 用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Phase 4

Not yet recruiting

Conditions: Biliary Malignant Tumors

Interventions: Drug: Donafenib
Drug: capecitabine

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-20

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 70

Registration Number: NCT06685289

TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma with PVTT

Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS)
Drug: Donafenib

First Posted Date: 2024-10-17

Last Posted Date: 2024-10-17

Lead Sponsor: Fei Gao

Target Recruit Count: 40

Registration Number: NCT06646198

Locations: 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Not Applicable

Recruiting

Conditions: Hepatocellular Carcinoma
Microwave Ablation
Donafenib
Recurrent Tumor

Interventions: Procedure: Thermal ablation
Drug: Donafenib

First Posted Date: 2024-09-24

Last Posted Date: 2024-12-03

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 108

Registration Number: NCT06609876

Locations: 🇨🇳
Chinese PLA General hospital, Beijing, None Selected, China

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

Not Applicable

Recruiting

Conditions: Hepatocellular Carcinoma
Adjuvant Therapy

Interventions: Drug: Donafenib

First Posted Date: 2024-09-03

Last Posted Date: 2024-09-03

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 204

Registration Number: NCT06581315

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib
Drug: Sintilimab
Other: HAIC

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06512467

Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

Phase 4

Not yet recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Drug: Donafenib
Procedure: transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy
Drug: PD-1,PD-L1

First Posted Date: 2024-07-11

Last Posted Date: 2024-07-11

Lead Sponsor: Tongji Hospital

Target Recruit Count: 32

Registration Number: NCT06496815

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Thyroid Gland Carcinoma

Interventions: Drug: Anlotinib
Drug: Lenvatinib
Drug: Sorafenib
Drug: Donafenib
Drug: Everolimus
Drug: Apatinib
Drug: Dabrafenib + Trametinib
Drug: Cabozantinib
Drug: Vandetanib
Drug: Entrectinib
Drug: Pralsetinib
Drug: Larotrectinib

First Posted Date: 2024-07-01

Last Posted Date: 2024-12-05

Lead Sponsor: West China Hospital

Target Recruit Count: 75

Registration Number: NCT06482086

Locations: 🇨🇳
West China hospital, Chengdu, Sichuan, China

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting

Conditions: Hepatocellular Carcinoma Non-resectable

Interventions: Procedure: TACE
Drug: Bevacizumab plus Atezolizumab
Drug: apatinib plus camrelizumab
Drug: Bevacizumab Biosimilar IBI305 plus sintilimab
Drug: Lenvatinib
Drug: Anti-PD-1 monoclonal antibody
Drug: Donafenib
Drug: Sorafenib
Drug: Regorafenib

First Posted Date: 2023-02-08

Last Posted Date: 2024-06-13

Lead Sponsor: Tongji Hospital

Target Recruit Count: 300

Registration Number: NCT05717738

Locations: 🇨🇳
Optical Valley branch of Tongji hospital, Wuhan, Hubei, China
🇨🇳
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 1 locations

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting

Conditions: Hepatocellular Carcinoma Non-resectable

Interventions: Procedure: HAIC
Drug: apatinib plus camrelizumab
Drug: Bevacizumab Biosimilar IBI305 plus sintilimab
Drug: Donafenib
Drug: Bevacizumab plus Atezolizumab
Drug: Sorafenib
Drug: Lenvatinib
Drug: Regorafenib
Drug: Anti-PD-1 monoclonal antibody

First Posted Date: 2023-02-06

Last Posted Date: 2023-12-22

Lead Sponsor: Wan-Guang Zhang

Target Recruit Count: 300

Registration Number: NCT05713994

Locations: 🇨🇳
TongjiHospital, Wuhan, Hubei, China
🇨🇳
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib
Procedure: TACE

First Posted Date: 2022-10-13

Last Posted Date: 2023-07-13

Lead Sponsor: Beijing Tsinghua Chang Gung Hospital

Target Recruit Count: 20

Registration Number: NCT05576909

Locations: 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy